ClinicalTrials.gg
CompletedNCT00926367Updated May 20, 2015Results posted

Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications

A Phase 4 interventional study of Clindamycin and benzoyl peroxide and benzoyl peroxide 2.5% and adapalene 0.1% gel in Acne Vulgaris, sponsored by Stiefel, a GSK Company. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2015-05-20.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing clindamycin in Acne Vulgaris — 1 open to participants now, 2 under way, none of them phase 3. Clindamycin · Acne Vulgaris.

Enrollment
24th of 34
52 · median 117
Started
2009
with 7 others
Phase 4
16 of 34
1 open now
Registered
9th of 34
by date
Lead sponsor
10 of 34
Stiefel, a GSK Company

Among the 34 studies testing clindamycin in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 8 that started in 2009, is one of 16 in phase 4, and was the 9th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

1 of the 34 studies testing clindamycin in Acne Vulgaris is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About clindamycin

Clindamycin: first FDA approval 1970 (CLEOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing clindamycin in Acne Vulgaris, or all of them as a file.
02

Study summary

This is a single-blind (blinded expert grader), randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene gel and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product

Read the detailed description

This is a single-blind (blinded expert grader), parallel group, randomized, half-face study being conducted at one clinical site. On 1 side of the face, the subject will apply 1 of the 2 test products, a topical antibiotic and benzoyl peroxide or benzoyl peroxide and adapalene and the contra lateral side of the face will remain non-treated to serve as a control. Approximately 25-30 male and female healthy subjects will be randomly assigned to each product.

The subjects will be entered into a 2-week treatment phase. The once-daily applications for the study medication will be supervised at the site, Monday through Friday of each week. Subjects will apply the study product at home on Saturdays and Sundays.

A blinded expert grader will rate comparative product tolerance on each week day (excluding Saturdays and Sundays) during the study before study product is applied.

Subject questionnaires will be completed along with collection of all adverse events.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects 18 to 45 years of age or older, able to complete the study and comply with study instructions.
  • Female subjects of must have a negative pregnancy test. Sexually active women of childbearing potential participating in the study must have been using a medically acceptable form of
  • Capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements) before any protocol specific procedures are performed.
  • Is willing to discontinue use of all facial products (other than the cleanser provided and makeup or razor and facial shave product) on the face for the 3 days before their baseline/day 0 visit and use only the provided facial products and their normal makeup or razor and facial shaving product for the duration of the study.
  • Is willing to avoid sunburn, tanning, tanning beds or other excessive sun exposure. Understands that if their skin tone changes significantly during the study it will be necessary to discontinue their participation.

Exclusion criteria

Exclusion Criteria:

  • Male subjects that have facial beards (mustache and/or goatee is acceptable).
  • Is a Type I diabetic.
  • Has active or chronic skin allergies.
  • Has a history of acute or chronic disease that might interfere with, or increase the risk of study participation.
  • Has participated in other facial studies in the preceding 30 days or other clinical studies in preceding 14 days.
  • Had skin cancer treatment in preceding 12 months.
  • Has damaged skin on facial areas (eg, from sunburn, tattoos, scars).
  • Had any medical procedure (eg, laser resurfacing, chemical peels, plastic surgery) to facial areas in preceding 12 months.
  • Had any cosmetic procedure (eg, microdermabrasion, etc.) to facial areas within 8 weeks of the baseline visit.
  • Live in the same household as currently enrolled subjects.
  • Any other condition or factor the investigator or his duly assigned representative believes may affect the skin response or the interpretation of the test results.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Clinidamycin/ Benzoyl Peroxide

    Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide (BPO).

    Drug: Clindamycin and benzoyl peroxide

  • Active comparator
    Benzoyl peroxide and adapalene

    Once-daily applications, to the randomized side of the face either left or right, of benzoyl peroxide (BPO) and adapalene

    Drug: benzoyl peroxide 2.5% and adapalene 0.1% gel

Interventions

  • DrugClindamycin and benzoyl peroxide

    Drug pages: Clindamycin · Benzoyl Peroxide

    Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.

    Also known as: Duac® Topical Gel (clindamycin and benzoyl peroxide.

  • Drugbenzoyl peroxide 2.5% and adapalene 0.1% gel

    Drug page: Benzoyl Peroxide

    Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel

    Also known as: benzoyl peroxide gel and adapalene gel

06

What researchers measure

Primary outcomes

  1. Skin Erythema (Redness)

    Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion

    Time frame: Baseline, Day 1 through Day 14

  2. Skin Dryness

    The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

Secondary outcomes

  1. Skin Moisture and Hydration

    To assess skin moisture and hydration using transepidermal water loss (TEWL). Results are measured on a continuous scale. Higher values indicate greater water loss/ lower skin moisture levels. Evaporative water loss measurements provide an instrumental assessment of skin barrier function(one of the layers of the skin. Damage leads to a disruption of the barrier that is accompanied by elevated water loss rates and affects skin moisture and hydration. Higher values indicate greater water loss.

    Time frame: Baseline, Days 3, 7, and 14

  2. Skin Hydration

    The ability of an alternating current to flow through the stratum corneum is an indirect measure of its water content. The value recorded is expressed in microsiemens. Higher values indicate greater levels of skin hydration. Test results were compared to measurements from the other side of the face, which was not treated instead of referring to a normal range. A normal range does not exist for this measurement. Instead, the non-treated side of the face was used as a control to determine the normal level of skin hydration.

    Time frame: Baseline, 4 hrs. post 1st Treatment, Days 3, 7, and 14

  3. Self Assessment of Burning

    The amount of burning on the left and right cheek of each panelist. The scale used to evaluate burning is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  4. Self Assessment of Stinging

    The amount of stinging on the left and right cheek of each panelist. The scale used to evaluate stinging is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of stinging were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  5. Self Assessment of Dryness

    The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate dryness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  6. Self Assessment of Texture (Roughness)

    The amount of roughness on the left and right cheek of each panelist. The scale used to evaluate roughness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  7. Self Assessment of Pain

    The amount of pain on the left and right cheek of each panelist. The scale used to evaluate pain is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  8. Self Assessment of Crusting

    The amount of crusting on the left and right cheek of each panelist. The scale used to evaluate crusting is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  9. Self Assessment of Blistering

    The amount of blistering on the left and right cheek of each panelist. The scale used to evaluate blistering is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  10. Self Assessment of Oiliness

    The amount of oiliness on the left and right cheek of each panelist. The scale used to evaluate oiliness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

    Time frame: Baseline, Day 1 through Day 14

  11. Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How do you rate the comfort of the skin where you are currently treating with the study product? The subject replied using the following scale: 1. - Very Comfortable 2. - Comfortable 3. - Somewhat Comfortable 4. - Somewhat Uncomfortable 5. - Uncomfortable

    Time frame: Day 14

  12. Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How compliant were you with applying the study product each and every day? The subject replied using the following scale: 0 - Not Compliant at all (\<50%) 1. - Mostly Compliant (50%-79%) 2. - Very Compliant (80%-100%)

    Time frame: Day 14

  13. Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? The subject replied using the following scale: 1 - Yes 0 - No

    Time frame: Day 14

  14. Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult

    Time frame: Day 14

  15. Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: What was your overall satisfaction of the study product? The subject replied using the following scale: 1. - Very Satisfied 2. - Satisfied 3. - Neutral 4. - Unsatisfied 5. - Very Unsatisfied

    Time frame: Day 14

  16. Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?

    The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult

    Time frame: Day 14

07

Results

Posted Aug 4, 2011

Participant flow

Clinical research center.

Participant flow — Overall Study
MilestoneDuacEpiduo
Started2527
Completed2324
Not completed23
Withdrew: Withdrawal by subject01
Withdrew: Lost to follow-up10
Withdrew: Skin irritation12

Outcome measures

PrimarySkin Erythema (Redness)

Assessment of erythema as part of an evaluation of tolerance of two treatments: clindamycin and benzoyl peroxide or dapsone gel. This was done by visual assessment by an independent blinded grader using the grading scale shown below. Grade Description 0 None 2 Mild erythema 4 Moderate confluent erythema 6 Marked erythema with some edema 8 Marked erythema, edema, possible erosion

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · Units on a scale
Skin Erythema (Redness)
Units on a scaleDuacEpiduo
Baseline1.56 ± 0.921.89 ± 1.01
Day 12.62 ± 1.322.65 ± 0.94
Day 22.90 ± 1.232.52 ± 1.03
Day 33.08 ± 1.232.81 ± 1.02
Day 63.17 ± 1.333.13 ± 0.89
Day 73.07 ± 1.303.08 ± 1.01
Day 82.87 ± 1.242.98 ± 1.08
Day 92.78 ± 1.363.03 ± 0.99
Day 102.89 ± 1.222.94 ± 1.02
Day 132.85 ± 1.202.83 ± 1.21
Day 142.73 ± 1.202.56 ± 1.03
Statistical analysis
  • Duac vs Epiduo · Dunn's Multiple Comparisons Test · p = >0.05A two-tailed p≤ 0.05 was taken as the level of significance for all comparisons.
SecondarySkin Moisture and Hydration

To assess skin moisture and hydration using transepidermal water loss (TEWL). Results are measured on a continuous scale. Higher values indicate greater water loss/ lower skin moisture levels. Evaporative water loss measurements provide an instrumental assessment of skin barrier function(one of the layers of the skin. Damage leads to a disruption of the barrier that is accompanied by elevated water loss rates and affects skin moisture and hydration. Higher values indicate greater water loss.

Time frame:
Baseline, Days 3, 7, and 14
Reported as:
Mean · TEWL rates (gm/m2/hr)
Skin Moisture and Hydration
TEWL rates (gm/m2/hr)DuacEpiduo
Baseline11.50 ± 3.6513.07 ± 5.06
Day 311.38 ± 2.4915.85 ± 9.12
Day 714.51 ± 3.6521.65 ± 8.66
Day 1413.36 ± 3.3319.28 ± 8.10
PrimarySkin Dryness

The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate skin dryness is: Grade Description 0 None 2 Slight flaking 4 Moderate flaking/scaling 6 Marked scaling / slight fissuring 8 Severe scaling, fissuring Expert Grader assessments of dryness were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Skin Dryness
units on a scaleDuacEpiduo
Baseline0.12 ± 0.440.07 ± 0.27
Day 10.41 ± 0.850.25 ± 0.57
Day 20.32 ± 0.830.34 ± 0.59
Day 30.46 ± 0.910.55 ± 1.15
Day 60.61 ± 1.021.73 ± 1.76
Day 70.69 ± 1.161.85 ± 2.01
Day 80.60 ± 1.131.87 ± 2.04
Day 90.73 ± 1.282.29 ± 1.99
Day 100.56 ± 1.041.49 ± 1.77
Day 130.80 ± 1.331.26 ± 1.85
Day 140.79 ± 1.041.33 ± 1.75
Statistical analysis
  • Duac vs Epiduo · Dunn's Multiple Comparisons Test · p = >0.05 (A two-tailed p≤ 0.05 was taken as the level of significance for all comparisons.)
SecondarySkin Hydration

The ability of an alternating current to flow through the stratum corneum is an indirect measure of its water content. The value recorded is expressed in microsiemens. Higher values indicate greater levels of skin hydration. Test results were compared to measurements from the other side of the face, which was not treated instead of referring to a normal range. A normal range does not exist for this measurement. Instead, the non-treated side of the face was used as a control to determine the normal level of skin hydration.

Time frame:
Baseline, 4 hrs. post 1st Treatment, Days 3, 7, and 14
Reported as:
Mean · Microsiemens
Skin Hydration
MicrosiemensDuacEpiduo
Baseline378.06 ± 131.08392.09 ± 162.16
4 hrs Post 1st Treatment323.47 ± 154.30415.90 ± 197.57
Day 3420.97 ± 122.60465.25 ± 175.65
Day 7385.91 ± 156.69414.77 ± 154.46
Day 14401.98 ± 156.08418.51 ± 139.64
SecondarySelf Assessment of Burning

The amount of burning on the left and right cheek of each panelist. The scale used to evaluate burning is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Burning
units on a scaleDuacEpiduo
Baseline0.00 ± 0.000.00 ± 0.00
Day 10.04 ± 0.200.04 ± 0.19
Day 20.04 ± 0.200.04 ± 0.19
Day 30.12 ± 0.330.15 ± 0.36
Day 60.12 ± 0.330.56 ± 0.85
Day 70.17 ± 0.480.70 ± 0.87
Day 80.17 ± 0.480.50 ± 0.81
Day 90.13 ± 0.450.27 ± 0.67
Day 100.13 ± 0.450.31 ± 0.68
Day 130.08 ± 0.280.35 ± 0.75
Day 140.08 ± 0.280.19 ± 0.57
SecondarySelf Assessment of Stinging

The amount of stinging on the left and right cheek of each panelist. The scale used to evaluate stinging is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of stinging were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Stinging
units on a scaleDuacEpiduo
Baseline0.00 ± 0.000.00 ± 0.00
Day 10.08 ± 0.280.00 ± 0.00
Day 20.08 ± 0.280.00 ± 0.00
Day 30.12 ± 0.440.04 ± 0.19
Day 60.1 ± 0.40.4 ± 0.8
Day 70.17 ± 0.480.30 ± 0.67
Day 80.17 ± 0.480.35 ± 0.69
Day 90.13 ± 0.450.15 ± 0.54
Day 100.13 ± 0.450.12 ± 0.43
Day 130.13 ± 0.340.19 ± 0.57
Day 140.08 ± 0.280.12 ± 0.43
SecondarySelf Assessment of Dryness

The amount of dryness on the left and right cheek of each panelist. The scale used to evaluate dryness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Dryness
units on a scaleDuacEpiduo
Baseline0.24 ± 0.440.30 ± 0.54
Day 10.2 ± 0.40.19 ± 0.40
Day 20.16 ± 0.370.15 ± 0.36
Day 30.24 ± 0.440.2 ± 0.4
Day 60.48 ± 0.770.67 ± 0.96
Day 70.54 ± 0.720.70 ± 0.91
Day 80.54 ± 0.780.81 ± 1.02
Day 90.54 ± 0.780.85 ± 1.01
Day 100.50 ± 0.780.69 ± 0.88
Day 130.50 ± 0.780.73 ± 0.96
Day 140.46 ± 0.720.69 ± 1.05
SecondarySelf Assessment of Texture (Roughness)

The amount of roughness on the left and right cheek of each panelist. The scale used to evaluate roughness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Texture (Roughness)
units on a scaleDuacEpiduo
Baseline0.28 ± 0.540.15 ± 0.36
Day 10.20 ± 0.500.07 ± 0.27
Day 20.16 ± 0.470.07 ± 0.27
Day 30.32 ± 0.690.07 ± 0.27
Day 60.28 ± 0.680.33 ± 0.78
Day 70.33 ± 0.760.19 ± 0.56
Day 80.25 ± 0.610.3 ± 0.7
Day 90.29 ± 0.690.15 ± 0.46
Day 100.29 ± 0.690.15 ± 0.46
Day 130.33 ± 0.700.12 ± 0.43
Day 140.29 ± 0.690.15 ± 0.46
SecondarySelf Assessment of Pain

The amount of pain on the left and right cheek of each panelist. The scale used to evaluate pain is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Pain
units on a scaleDuacEpiduo
Baseline0.00 ± 0.000.00 ± 0.00
Day 10.04 ± 0.200.04 ± 0.19
Day 20.04 ± 0.200.00 ± 0.00
Day 30.04 ± 0.200.00 ± 0.00
Day 60.04 ± 0.200.1 ± 0.4
Day 70.04 ± 0.200.04 ± 0.19
Day 80.04 ± 0.200.04 ± 0.20
Day 90.04 ± 0.200.00 ± 0.00
Day 100.04 ± 0.200.00 ± 0.00
Day 130.04 ± 0.200.00 ± 0.00
Day 140.04 ± 0.200.00 ± 0.00
SecondarySelf Assessment of Crusting

The amount of crusting on the left and right cheek of each panelist. The scale used to evaluate crusting is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Crusting
units on a scaleDuacEpiduo
Baseline0.00 ± 0.000.00 ± 0.00
Day 10.00 ± 0.000.00 ± 0.00
Day 20.00 ± 0.000.00 ± 0.00
Day 30.00 ± 0.000.00 ± 0.00
Day 60.00 ± 0.000.07 ± 0.38
Day 70.00 ± 0.000.04 ± 0.19
Day 80.00 ± 0.000.04 ± 0.20
Day 90.00 ± 0.000.04 ± 0.20
Day 100.00 ± 0.000.04 ± 0.20
Day 130.00 ± 0.000.00 ± 0.00
Day 140.00 ± 0.000.00 ± 0.00
SecondarySelf Assessment of Blistering

The amount of blistering on the left and right cheek of each panelist. The scale used to evaluate blistering is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Blistering
units on a scaleDuacEpiduo
Baseline0.00 ± 0.000.00 ± 0.00
Day 10.00 ± 0.000.00 ± 0.00
Day 20.00 ± 0.000.00 ± 0.00
Day 30.00 ± 0.000.00 ± 0.00
Day 60.00 ± 0.000.07 ± 0.38
Day 70.00 ± 0.000.04 ± 0.19
Day 80.00 ± 0.000.00 ± 0.00
Day 90.00 ± 0.000.00 ± 0.00
Day 100.00 ± 0.000.00 ± 0.00
Day 130.00 ± 0.000.00 ± 0.00
Day 140.00 ± 0.000.00 ± 0.00
SecondarySelf Assessment of Oiliness

The amount of oiliness on the left and right cheek of each panelist. The scale used to evaluate oiliness is: Scale Description: (scale: 0 = none to 3 = severe) Subject Self Assessments of burning were taken prior to product application on Days 0, 1, 2, 3, 6, 7, 8, 9, 10, 13 and 14.

Time frame:
Baseline, Day 1 through Day 14
Reported as:
Mean · units on a scale
Self Assessment of Oiliness
units on a scaleDuacEpiduo
Baseline0.12 ± 0.330.19 ± 0.40
Day 10.08 ± 0.280.11 ± 0.42
Day 20.00 ± 0.000.04 ± 0.19
Day 30.08 ± 0.280.11 ± 0.42
Day 60.04 ± 0.200.04 ± 0.19
Day 70.00 ± 0.000.07 ± 0.27
Day 80.00 ± 0.000.04 ± 0.20
Day 90.00 ± 0.000.08 ± 0.27
Day 100.00 ± 0.000.0 ± 0.2
Day 130.00 ± 0.000.12 ± 0.43
Day 140.00 ± 0.000.08 ± 0.27
SecondaryProduct Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How do you rate the comfort of the skin where you are currently treating with the study product? The subject replied using the following scale: 1. - Very Comfortable 2. - Comfortable 3. - Somewhat Comfortable 4. - Somewhat Uncomfortable 5. - Uncomfortable

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - How do You Rate the Comfort of the Skin Where You Are Currently Treating With the Study Product?2.38 ± 1.132.23 ± 1.24
SecondaryProduct Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: How compliant were you with applying the study product each and every day? The subject replied using the following scale: 0 - Not Compliant at all (\<50%) 1. - Mostly Compliant (50%-79%) 2. - Very Compliant (80%-100%)

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - How Compliant Were You With Applying the Study Product Each and Every Day?2.00 ± 0.002.00 ± 0.00
SecondaryProduct Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Did you feel that your skin was hydrated and moisturized while you were on your study product? The subject replied using the following scale: 1 - Yes 0 - No

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - Did You Feel That Your Skin Was Hydrated and Moisturized While You Were on Your Study Product?0.58 ± 0.500.54 ± 0.51
SecondaryProduct Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - Was the Study Product Easy to Use With Make-up?1.04 ± 1.121.46 ± 1.14
SecondaryProduct Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: What was your overall satisfaction of the study product? The subject replied using the following scale: 1. - Very Satisfied 2. - Satisfied 3. - Neutral 4. - Unsatisfied 5. - Very Unsatisfied

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - What Was Your Overall Satisfaction of the Study Product?2.29 ± 1.042.46 ± 1.03
SecondaryProduct Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?

The subject were presented with a questionnaire at day 14 (end of study) and was asked the following question: Was the study product easy to use with make-up? The subject replied using the following scale: 0 - Not Applicable 1. - Very Easy 2. - Easy 3. - Neutral 4. - Difficult 5. - Very Difficult

Time frame:
Day 14
Reported as:
Mean · units on a scale
Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?
units on a scaleDuacEpiduo
Product Acceptability and Preference Questionnaire - How do You Rate the Ease of Application of the Study Product?1.17 ± 0.381.00 ± 0.00

Adverse events

Collected over 14 days. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Duac—0/25 (0%)13/25 (52%)
Epiduo—0/27 (0%)13/27 (48.1%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDuacEpiduo
HeadacheNervous system disorders4/255/27
InsomniaPsychiatric disorders3/250/27
Menstrual crampsMusculoskeletal and connective tissue disorders3/252/27
Sore throatGeneral disorders2/253/27
EaracheInfections and infestations0/253/27
IrritationSkin and subcutaneous tissue disorders2/252/27
Upper respiratory tract infectionInfections and infestations2/250/27
ToothacheGeneral disorders2/251/27
Joint stiffnessMusculoskeletal and connective tissue disorders0/252/27
Seaonal allergiesInfections and infestations1/250/27

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)DuacEpiduoTotal
<=18 years112
Between 18 and 65 years242650
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)DuacEpiduoTotal
Female232649
Male213
Region of Enrollment
Region of Enrollment(participants)DuacEpiduoTotal
United States252752
08

Study locations

1 site
  • cyberDERM
    Broomall, Pennsylvania 19008, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Jun 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2011, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2009
First posted
Jun 23, 2009
Start
May 2009
Primary completionActual
Jun 2009
CompletionActual
Jul 2009
Results first posted
Aug 4, 2011
Last update
May 20, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00926367
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 23, 2009
Start date
May 2009
Primary completion
Jun 2009
Completion
Jul 2009
Results posted
Aug 4, 2011
Last update
May 20, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Clindamycin · Benzoyl Peroxide

Start the discussion